Why Is NovoEight So Hard to Find? [Explained for 2026]

If you or a family member has hemophilia A and relies on NovoEight (turoctocog alfa) for bleeding control, you already know that filling this prescription is nothing like picking up a bottle of ibuprofen at the corner drugstore. NovoEight is a specialty biologic medication that requires a specific distribution channel — and that means most patients run into real barriers when trying to access it quickly.

This guide explains exactly why NovoEight can be hard to find, what channels carry it, and what steps you can take to make sure your supply never runs out.

What Makes NovoEight Different From Most Medications?

NovoEight is not a pill you can pick up at a standard retail pharmacy. It is a recombinant factor VIII replacement therapy manufactured by Novo Nordisk and administered by intravenous (IV) injection. It is specifically approved for adults and children with hemophilia A — a rare genetic bleeding disorder caused by a deficiency in clotting factor VIII.

Because of its complexity, NovoEight is classified as a specialty medication and is only distributed through specialty pharmacies — not standard retail or mail-order chains. Specialty pharmacies like CVS Specialty are equipped to handle the cold-chain storage, insurance authorization, and clinical support that biologics like NovoEight require.

Why Does Specialty-Only Distribution Create Access Problems?

Specialty pharmacy distribution creates several potential access bottlenecks:

Limited network: Not every specialty pharmacy carries every hemophilia product. Your insurance plan may only reimburse through one or two in-network specialty pharmacies.

Prior authorization delays: Most insurance plans require prior authorization (PA) before covering NovoEight. PA approvals can take days or even weeks, leaving patients without medication in the meantime.

Inventory management: Because hemophilia A is a rare condition affecting about 1 in every 5,000 male births in the US, some specialty pharmacies carry limited inventory of specific vial strengths.

Delivery timing: Specialty medications are typically shipped rather than picked up in store. This means patients must plan ahead and can't get a same-day fill in an emergency.

Is NovoEight in a Drug Shortage in 2026?

NovoEight (turoctocog alfa) does not appear on the FDA's current drug shortage list. Unlike many generic injectable medications that suffer from manufacturing concentration and low margins, NovoEight is a branded specialty biologic manufactured by Novo Nordisk under controlled and well-resourced conditions.

That said, access problems are real even for non-shortage drugs. Insurance coverage issues, prior authorization denials, and specialty pharmacy network restrictions can make it just as hard to get NovoEight in your hands as an active shortage drug.

What Role Does the Hemophilia Treatment Center (HTC) Play?

Most patients with hemophilia A are connected to a Hemophilia Treatment Center (HTC) — a specialized clinic that coordinates all aspects of hemophilia care, including factor prescriptions, physical therapy, and social work support. HTCs typically have established relationships with specialty pharmacies and can help coordinate your NovoEight supply.

If you are not currently connected to an HTC, the National Bleeding Disorders Foundation (NBDF) maintains a directory of HTCs across the United States at bleeding.org. Getting connected to an HTC is one of the most effective ways to reduce access problems for specialty hemophilia medications.

What Are the Insurance Coverage Barriers for NovoEight?

Hemophilia A therapies including NovoEight are among the most expensive medications in the world. Annual treatment costs for hemophilia A factor replacement can range from tens of thousands to hundreds of thousands of dollars per year depending on body weight, dosing regimen, and factor type.

Because of this, most commercial insurance plans and Medicaid programs impose strict prior authorization requirements. Some plans also apply step therapy, requiring patients to try other factor products before approving NovoEight. These hurdles can delay treatment by days or weeks.

What Storage Requirements Make NovoEight Unique?

One feature that sets NovoEight apart from competitor factor VIII products is its exceptional storage stability. NovoEight is the only standard half-life factor VIII that can be stored at temperatures up to 104°F for up to 3 months — compared to standard refrigeration for most competitors. After reconstitution, it can be used for up to 4 hours at room temperature (up to 86°F).

This makes NovoEight a good choice for active patients who travel frequently or live in warmer climates — but the specialty distribution system still applies regardless of storage advantages.

How Can medfinder Help You Find NovoEight?

When you need to verify which specialty pharmacy in your area has your specific strength of NovoEight available, medfinder can help. medfinder calls pharmacies on your behalf to check which ones can fill your specific prescription — saving you hours of phone calls and uncertainty.

For more step-by-step tips on locating NovoEight, read our companion guide: How to Find NovoEight In Stock Near You (Tools + Tips).

Key Takeaways

NovoEight is a specialty biologic only available through specialty pharmacies — not standard retail pharmacies.

Access barriers come mainly from insurance prior authorization and limited specialty pharmacy networks, not drug shortages.

Connecting with a Hemophilia Treatment Center (HTC) is the best way to streamline your factor supply.

Novo Nordisk's NovoCare program offers copay support and patient assistance for eligible patients.

NovoEight's unique 104°F storage stability makes it especially convenient for active, traveling patients.